Journal of Neurogastroenterology and Motility

The Korean Society of Neurogastroenterology and Motility (대한소화기 기능성질환 운동학회)
권호 표지
DOI QR코드

DOI QR Code

Sex-Gender Differences in Irritable Bowel Syndrome

  • Kim, Young Sun (Department of Internal Medicine, Healthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center) ;
  • Kim, Nayoung (Seoul National University Bundang Hospital)
  • Received : 2018.05.10
  • Accepted : 2018.08.24
  • Published : 2018.10.30
⟨ Previous Next ⟩

Abstract

Because of the sex-gender differences that are shown in a diversity of physiological and psychological factors, it can be speculated that the clinical presentation of symptoms as well as treatment strategies in women and men with irritable bowel syndrome (IBS) may differ. Studies have revealed that IBS is more common in women than men. As for the IBS subtype, IBS with constipation is significantly more prevalent among women than men. Sex hormones and gender differences may play important roles in the pathophysiology of IBS. However, its pathophysiologic mechanisms still remain largely unknown, and therapeutic implications are limited. Moreover, women IBS patients have been reported to feel more fatigue, depression, anxiety, and lower quality of life than men IBS patients. Furthermore, there has been evidence of differences in the appropriate treatment efficacy to IBS in men and women, although relatively few men are enrolled in most relevant clinical trials. A more sex-gender-oriented approach in the medical care setting could improve understanding of heterogeneous patients suffering from IBS. An individualized and multicomponent approach including sex and gender issues might help improve the treatment of IBS.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional Bowel Disorders. Gastroenterology 2006;130:1480-1491. https://doi.org/10.1053/j.gastro.2005.11.061
  2. Houghton LA, Heitkemper M, Crowell M, et al. Age, gender and women's health and the patient. Gastroenterology 2016;150:1332-1343, e4. https://doi.org/10.1053/j.gastro.2016.02.017
  3. Wizemann TM, Pardue ML. Exploring the biological contributions to human health: does sex matter? Washington, DC: National Academies Press; 2001.
  4. Kim YS, Kim N, Kim GH. Sex and gender differences in gastroesophageal reflux disease. J Neurogastroenterol Motil 2016;22:575-588. https://doi.org/10.5056/jnm16138
  5. Kilminster S, Downes J, Gough B, Murdoch-Eaton D, Roberts T. Women in medicine-is there a problem? A literature review of the changing gender composition, structures and occupational cultures in medicine. Medical Educ 2007;41:39-49. https://doi.org/10.1111/j.1365-2929.2006.02645.x
  6. Annandale E, Hammarstrom A. Constructing the 'gender-specific body': a critical discourse analysis of publications in the field of genderspecific medicine. Health 2011;15:571-587. https://doi.org/10.1177/1363459310364157
  7. Ahlawat SK, Cuddihy MT, Locke GR 3rd. Gender-related differences in dyspepsia: a qualitative systematic review. Gender Med 2006;3:31-42. https://doi.org/10.1016/S1550-8579(06)80192-0
  8. Flier SN, Rose S. Is functional dyspepsia of particular concern in women? A review of gender differences in epidemiology, pathophysiologic mechanisms, clinical presentation, and management. Am J Gastroenterol 2006;101(12 suppl):S644-S653.
  9. Welen K, Faresjo A, Faresjo T. Functional dyspepsia affects women more than men in daily life: a case-control study in primary care. Gender Med 2008;5:62-73. https://doi.org/10.1016/S1550-8579(08)80009-5
  10. Boeckxstaens GE, Drug V, Dumitrascu D, et al. Phenotyping of subjects for large scale studies on patients with IBS. Neurogastroenterol Motil 2016;28:1134-1147. https://doi.org/10.1111/nmo.12886
  11. Talley NJ. Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol 1999;13:371-384. https://doi.org/10.1016/S1521-6942(99)90025-6
  12. Chial HJ, Camilleri M. Gender differences in irritable bowel syndrome. J Gend Specif Med 2002;5:37-45.
  13. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012;107:991-1000. https://doi.org/10.1038/ajg.2012.131
  14. Song KH, Jung HK, Kim HJ, et al. Clinical practice guidelines for irritable bowel syndrome in Korea, 2017 revised edition. J Neurogastroenterol Motil 2018;24:197-215. https://doi.org/10.5056/jnm17145
  15. Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology 2002;123:1686-1701. https://doi.org/10.1053/gast.2002.36603
  16. Adeyemo MA, Spiegel BM, Chang L. Meta-analysis: do irritable bowel syndrome symtomes vary between men and wome? Aliment Pharmacol Ther 2010;32:738-755. https://doi.org/10.1111/j.1365-2036.2010.04409.x
  17. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-2131. https://doi.org/10.1053/gast.2002.37095
  18. Muller-Lissner SA, Bollani S, Brummer RJ, et al. Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion 2001;64:200-204. https://doi.org/10.1159/000048862
  19. Sperber AD, Dumitrascu D, Fukudo S, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a rome foundation working team literature reviw. Gut 2017;66:1075-1085. https://doi.org/10.1136/gutjnl-2015-311240
  20. Ghoshal UC, Abraham P, Bhatt C, et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the India society of gastroenterology task force. Indian J Gastroenterol 2008;27:22-28.
  21. Lee OY. Asian motility studies in irritable bowel syndrome. J Neurogastroenterol Motil 2010;16:120-130. https://doi.org/10.5056/jnm.2010.16.2.120
  22. Toner BB, Akman D. Gender role and irritable bowel syndrome: literature review and hypothesis. Am J Gastroenterol 2000;95:11-16. https://doi.org/10.1111/j.1572-0241.2000.01698.x
  23. Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil 2011;17:14-27. https://doi.org/10.5056/jnm.2011.17.1.14
  24. Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology 2017;152:1042-1054.e1. https://doi.org/10.1053/j.gastro.2016.12.039
  25. Mulak A, Tache Y. Sex difference in irritable bowel syndrome: do gonadal hormones play a role? Gastroenterol Pol 2010;17:89-97.
  26. Garcia Rodriguez LA, Ruigomez A, Wallander MA, Johansson S, Olbe L. Defection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Scand J Gastroenterol 2000;35:306-311. https://doi.org/10.1080/003655200750024191
  27. Heitkemper MM, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med 2009;6(suppl 2):152-167. https://doi.org/10.1016/j.genm.2009.03.004
  28. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-1491. https://doi.org/10.1053/j.gastro.2005.11.061
  29. Mulak A, Waszczuk E, Paradowski L. Irritable bowel syndrome as an interdisciplinary clinical problem. Adv Clin Exp Med 2008;17:667-675.
  30. Warnock JK, Clayton AH. Chronic episodic disorders in women. Psychiatr Clin North Am 2003;26:725-740. https://doi.org/10.1016/S0193-953X(03)00042-X
  31. Chang L, Toner BB, Fukudo S, et al. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 2006;130:1435-1446. https://doi.org/10.1053/j.gastro.2005.09.071
  32. Georgescu D, Reisz D, Gurban CV, et al. Migraine in young females with irritable bowel syndrome: still a challenge. Neuropsychiatr Dis Treat 2017;14:21-28. https://doi.org/10.2147/NDT.S144955
  33. Olafsdottir LB, Gudjonsson H, Jonsdottir HH, Bjornsson E, Thjodleifsson B. Natural history of irritable bowel syndrome in women and dysmenorrhea: a 10-year follow-up study. Gastroenterol Res Pract 2012;2012:534204.
  34. Choghakhori R, Abbasnezhad A, Amani R, Alipour M. Sex-related differences in clinical symptoms, quality of life, and biochemical factors in irritable bowel syndrome. Dig Dis Sci 2017;62:1550-1560. https://doi.org/10.1007/s10620-017-4554-6
  35. Heitkemper MM, Cain KC, Jarrett ME, Burr RL, Hertig V, Bond EF. Symptoms across the menstrual cycle in women with irritable bowel syndrome. Am J Gastroenterol 2003;98:420-430. https://doi.org/10.1111/j.1572-0241.2003.07233.x
  36. Ruigomez A, Garcia Rodriguez LA, Johansson S, Wallander MA. Is hormone replacement therapy associated with an increased risk of irritable bowel syndrome? Maturitas 2003;44:133-140. https://doi.org/10.1016/S0378-5122(02)00321-3
  37. Gonenne J, Esfandyari T, Camilleri M, et al. Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women. Neurogastroenterol Motil 2006;18:911-918. https://doi.org/10.1111/j.1365-2982.2006.00808.x
  38. Chandar AK. Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide. Int J Gen Med 2017;10:385-393. https://doi.org/10.2147/IJGM.S126581
  39. Harris LA, Umar SB, Baffy N, Heitkemper MM. Irritable bowel syndrome and female patients. Gastroenterol Clin North Am 2016;45:179-204. https://doi.org/10.1016/j.gtc.2016.02.001
  40. Drossman DA. Functional Gastrointestinal disorder: history, pathophysiology, and Rome IV. Gastroenterology 2016;150:1262-1279. https://doi.org/10.1053/j.gastro.2016.02.032
  41. Farhadi A, Banton D, Keefer L. Connecting our gut feeling and how our gut feels: the role of well-being attributes in irritable bowel syndrome. J Neurogastroenterol Motil 2018;24:289-298. https://doi.org/10.5056/jnm17117
  42. Meerveld BG, Johnson AC. Mechanisms of stress-induced visceral pain. J Neurogastroenterol Motil 2018;24:7-18. https://doi.org/10.5056/jnm17137
  43. Lee HF, Liu PY, Wang YP, Tsai CF, Chang FY, Lu CL. Sexual abuse is associated withan abnormal psychological profile and sleep difficulty in patients with irritable bowel syndrome in Taiwan. J Neurogastroenterol Motil 2018;24:79-86. https://doi.org/10.5056/jnm17004
  44. Choi YJ, Kim N, Yoon H, et al. Overlap between irritable bowel syndrome and functional dyspepsia including subtype analyses. J Gastroenterol Hepatol 2017;32:1553-1561. https://doi.org/10.1111/jgh.13756
  45. Lampe JW, Fredstrom SB, Slavin JL, Potter JD. Sex differences in colonic function: a randomised trial. Gut 1993;34:531-536. https://doi.org/10.1136/gut.34.4.531
  46. Meleine M, Matricon J. Gender-related differences in irritable bowel syndrome: potential mechanisms of sex hormones. World J Gastroenterol 2014;20:6725-6743. https://doi.org/10.3748/wjg.v20.i22.6725
  47. Aloisi AM. Gonadal hormones and sex differences in pain reactivity. Clin J Pain 2003;19:168-174. https://doi.org/10.1097/00002508-200305000-00004
  48. Cairns BE, Gazerani P. Sex-related differences in pain. Maturitas 2009;63:292-296. https://doi.org/10.1016/j.maturitas.2009.06.004
  49. Houghton LA, Jackson NA, Whorwell PJ, Morris J. Do male sex hormones protect from irritable bowel syndrome? Am J Gastroenterol 2000;95:2296-2300. https://doi.org/10.1111/j.1572-0241.2000.02314.x
  50. Kim BJ, Rhee PL, Park JH, et al. Male sex hormones may influence the symptoms of irritable bowel syndrome in young men. Digestion 2008;78:88-92. https://doi.org/10.1159/000166600
  51. Miller V, Whitaker K, Morris JA, Whorwell PJ. Gender and irritable bowel syndrome: the male connection. J Clin Gastroenterol 2004;38:558-560. https://doi.org/10.1097/00004836-200408000-00004
  52. Aloisi AM, Bachiocco V, Costantino A, et al. Cross-sex hormone administration changes pain in transsexual women and men. Pain 2007;132:S60-S67. https://doi.org/10.1016/j.pain.2007.02.006
  53. Chang L, Mayer EA, Labus JS, et al. Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. Am J Physiol Regul Integr Comp Physiol 2006;291:R277-R284. https://doi.org/10.1152/ajpregu.00729.2005
  54. Ragnarsson G, Hallbook O, Bodemar G. Abdominal symptoms are not related to anorectal function in the irritable bowel syndrome. Scand J Gastroenterol 1999;34:250-258.
  55. Naliboff BD, Berman S, Chang L, et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003;124:1738-1747. https://doi.org/10.1016/S0016-5085(03)00400-1
  56. Chang L, Adeyemo M, Karagiannides I, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012;107:262-272. https://doi.org/10.1038/ajg.2011.423
  57. Martin-Vinas JJ, Quigley EM. Immune response in irritable bowel syndrome: a systematic review of systemic and mucosal inflammatory mediators. J Dig Dis 2016;17:572-581. https://doi.org/10.1111/1751-2980.12379
  58. Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009;104:392-400. https://doi.org/10.1038/ajg.2008.94
  59. Bashashati M, Rezaei N, Shafieyoun A, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 2014;26:1036-1048. https://doi.org/10.1111/nmo.12358
  60. Pigrau M, Rodino-Janeiro BK, Casado-Bedmar M, et al. The joint power of sex and stress to modulate brain-gut microbiota axis and intestinal barrierhomeostasis: implications for irritable bowel syndrome. Neurogastroenterol Motil 2016;28:463-486. https://doi.org/10.1111/nmo.12717
  61. Lee JY, Kim N, Kim YS, et al. Repeated water avoidance stress alters mucosal mast cell counts, interleukin-$1{\beta}$ levels with sex difference in distal colon of wistar rats. J Neurogastroenterol Motil 2016;22:694-704. https://doi.org/10.5056/jnm16007
  62. Mulak A, Tache Y, Larauche M. Sex hormones in the modulation of irritable bowel syndrome. World J Gastroenterol 2014;20:2433-2448. https://doi.org/10.3748/wjg.v20.i10.2433
  63. Zheng G, Wu SP, Hu Y, Smith DE, Wiley JW, Hong S. Corticosterone mediates stress-related increased intestinal permeability in a regionspecific manner. Neurogastroenterol Motil 2013;25:e127-e139. https://doi.org/10.1111/nmo.12066
  64. Honda J, Iijima K, Asanuma K, et al. Estrogen enhances esophageal barrier function by potentiating occludin expression. Dig Dis Sci 2016;61:1028-1038. https://doi.org/10.1007/s10620-015-3980-6
  65. Cotter AA, Cashman KD. Effect of 17beta-oestradiol on transepithelial calcium transport in human intestinal-like Caco-2 cells and its interactions with 1,25-dihydroxycholecalciferol and 9-cis retinoic acid. Eur J Nutr 2006;45:234-241. https://doi.org/10.1007/s00394-006-0590-2
  66. Braniste V, Leveque M, Buisson-Brenac C, Bueno L, Fioramonti J, Houdeau E. Oestradiol decreases colonic permeability through oestrogen receptor beta-mediated up-regulation of occludin and junctional adhesion molecule-A in epithelial cells. J Physiol 2009;587(Pt 13):3317-3328. https://doi.org/10.1113/jphysiol.2009.169300
  67. Braniste V, Jouault A, Gaultier E, et al. Impact of oral bisphenol A at reference doses on intestinal barrier function and sex differences after perinatal exposure in rats. Proc Natl Acad Sci USA 2010;107:448-453. https://doi.org/10.1073/pnas.0907697107
  68. Moussa L, Bezirard V, Salvador-Cartier C, Bacquie V, Houdeau E, Theodorou V. A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndromelike symptoms in stressed female rats. Clin Nutr 2013;32:51-58. https://doi.org/10.1016/j.clnu.2012.05.021
  69. Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: new therapeutic strategies. World J Gastroenterol 2016;22:2219-2241. https://doi.org/10.3748/wjg.v22.i7.2219
  70. Ait-Belgnaoui A, Payard I, Rolland C, et al. Bifidobacterium longum and Lactobacillus helveticus synergistically suppress stress-related visceral hypersensitivity through hypothalamic-pituitary-adrenal axis modulation. J Neurogastroenterol Motil 2018;24:138-146. https://doi.org/10.5056/jnm16167
  71. Menon R, Watson SE, Thomas LN, et al. Diet complexity and estrogen receptor $\beta$ status affect the composition of the murine intestinal microbiota. Appl Environ Microbiol 2013;79:5763-5773. https://doi.org/10.1128/AEM.01182-13
  72. Markle JG, Frank DN, Mortin-Toth S, et al. Sex differences in the gut microbiome drive hormone dependent regulation of autoimmunity. Science 2013;339:1084-1088. https://doi.org/10.1126/science.1233521
  73. Mattar AF, Teitelbaum DH, Drongowski RA, Yongyi F, Harmon CM, Coran AG. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int 2002;18:586-590. https://doi.org/10.1007/s00383-002-0855-7
  74. Kim Y, Kim SH, Whang KY, Kim YJ, Oh S. Inhibition of Escherichia coli O157: H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells. J Microbiol Biotechnol 2008;18:1278-1285.
  75. Da Silva S, Robbe-Masselot C, Ait-Belgnaoui A, et al. Stress disrupts intestinal mucus barrier in rats via mucin O-glycosylation shift: prevention by a probiotic treatment. Am J Physiol Gastrointest Liver Physiol 2014;307:G420-G429. https://doi.org/10.1152/ajpgi.00290.2013
  76. Shastri P, McCarville J, Kalmokoff M, Brooks SP, Green-Johnson JM. Sex differences in gut fermentation and immune parameters in rats fed an oligofructose-supplemented diet. Biol Sex Differ 2015;6:13. https://doi.org/10.1186/s13293-015-0031-0
  77. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012;489:242-249. https://doi.org/10.1038/nature11552
  78. Kim SY, Choung RS, Lee SK, et al. Self reported sleep impairment in functional dyspepsia and irritable bowel syndrome. J Neurogastroenterol Motil 2018;24:280-288. https://doi.org/10.5056/jnm17098
  79. Simren M, Abrahamsson H, Svedlund J, Bjornsson ES. Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. Scand J Gastroenterol 2001;36:545-552. https://doi.org/10.1080/00365520120438
  80. Choi YJ, Park YS, Kim N, et al. Gender differences in ghrelin, nociception genes, psychological factors and quality of life in functional dyspepsia. World J Gastroenterol 2017;23:8053-8061. https://doi.org/10.3748/wjg.v23.i45.8053
  81. Park JM, Choi MG, Kim YS, et al. Quality of life of patients with irritable bowel syndrome in Korea. Qual Life Res 2009;18:435-446. https://doi.org/10.1007/s11136-009-9461-7
  82. Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res 1990;34:483-491. https://doi.org/10.1016/0022-3999(90)90022-V
  83. Faresjo A, Grodzinsky E, Johansson S, Wallander MA, Timpka T, Akerlind I. A population-based case-control study of work and psychosocial problems in patients with irritable bowel syndrome-women are more seriously affected than men. Am J Gastroenterol 2007;102:371-379. https://doi.org/10.1111/j.1572-0241.2006.01012.x
  84. Halder SL, Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Impact of functional gastrointestinal disorders on healthrelated quality of life: a population-based case-control study. Aliment Pharmacol Ther 2004;19:233-242. https://doi.org/10.1111/j.0269-2813.2004.01807.x
  85. Michalsen VL, Vandvik PO, Farup PG. Predictors of health-related quality of life in patients with irritable bowel syndrome. A cross-sectional study in Norway. Health Qual Life Outcomes 2015;13:113. https://doi.org/10.1186/s12955-015-0311-8
  86. Hulme K, Chilcot J, Smith MA. Doctor-patient relationship and quality of life in irritable bowel syndrome: an exploratory study of the potential mediating role of illness perceptions and acceptance. Psychol Health Med 2018;23:674-684. https://doi.org/10.1080/13548506.2017.1417613
  87. Frissora CL, Koch KL. The role of gender and biological sex in irritable bowel syndrome. Curr Gastroenterol Rep 2005;7:257-263. https://doi.org/10.1007/s11894-005-0017-x
  88. Cheney AM. "Most girls want to be skinny": body (dis)satisfaction among ethnically diverse women. Qual Health Res 2011;21:1347-1359. https://doi.org/10.1177/1049732310392592
  89. Payne S. Sex, gender, and irritable bowel syndrome: making the connections. Gend Med 2004;1:18-28. https://doi.org/10.1016/S1550-8579(04)80007-X
  90. Ali A, Toner BB, Stuckless N, et al. Emotional abuse, self-blame and self-silencing in women with irritable bowel syndrome. Psychosom Med 2000;62:76-82. https://doi.org/10.1097/00006842-200001000-00011
  91. Bjorkman I, Dellenborg L, Ringstrom G, Simren M, Jakobsson Ung E. The gendered impact of irritable bowel syndrome: a qualitative study of patients' experiences. J Adv Nurs 2014;70:1334-1343. https://doi.org/10.1111/jan.12294
  92. Pimentel M, Lembo A, Chey WD, et al.. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32. https://doi.org/10.1056/NEJMoa1004409
  93. El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord 2003;3(suppl 2):S3-S11.
  94. Gibson PR,Varney J, Malakar S, Muir JG. Food components and irritable bowel syndrome. Gastroenterology 2015;148:1158-1174, e4. https://doi.org/10.1053/j.gastro.2015.02.005
  95. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551. https://doi.org/10.1053/j.gastro.2004.11.050
  96. Ouyang A, Wrzos HF. Contribution of gender to pathophysiology and clinical presentation of IBS: should management be different in women? Am J Gastroenterol 2006;101(12 suppl):S602-S609.
  97. Lunsford TN, Harris LA. Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. Int J Womens Health 2010;2:361-374.
  98. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-1159. https://doi.org/10.1046/j.1365-2036.1999.00610.x
  99. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035-1040. https://doi.org/10.1016/S0140-6736(00)02033-X
  100. Katsumata R, Shiotani A, Murao T, et al. Gender differences in serotonin signaling in patients with diarrhea-predominant irritable bowel syndrome. Intern Med 2017;56:993-999. https://doi.org/10.2169/internalmedicine.56.7674
  101. Scott LJ, Perry CM. Tegaserod. Drugs 1999;58:491-496; discussion 497-498. https://doi.org/10.2165/00003495-199958030-00013
  102. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005;100:115-123. https://doi.org/10.1111/j.1572-0241.2005.40365.x
  103. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009;104:1831-1843. https://doi.org/10.1038/ajg.2009.223
  104. Zheng Y, Yu T, Tang Y, et al. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2017;12:e0172846. https://doi.org/10.1371/journal.pone.0172846
  105. Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 2009;19:141-150, vii. https://doi.org/10.1016/j.giec.2008.12.004
  106. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002;123:425-432. https://doi.org/10.1053/gast.2002.34780
  107. Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2014;63:1617-1625. https://doi.org/10.1136/gutjnl-2013-305989
  108. Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 2011;23:1098-1104. https://doi.org/10.1111/j.1365-2982.2011.01771.x
  109. Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2014;12:953-959.e4. https://doi.org/10.1016/j.cgh.2013.11.024
  110. Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology 2016;150:358-366.e8. https://doi.org/10.1053/j.gastro.2015.10.047
  111. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 2016;151:1113-1121. https://doi.org/10.1053/j.gastro.2016.08.003
  112. Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2014;109:1350-1365. https://doi.org/10.1038/ajg.2014.148
  113. Lee HH, Choi YY, Choi MG. The Efficacy of hypnotherapy in the treatment of irritable bowel syndrome: a systematic reviewand metaanalysis. J Neurogastroenterol Motil 2014;20:152-162. https://doi.org/10.5056/jnm.2014.20.2.152
  114. Ustun TB. Cross-national epidemiology of depression and gender. J Gend Specif Med 2000;3:54-58.
  115. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25:1351-1361. https://doi.org/10.1111/j.1365-2036.2007.03320.x
  116. Buscail C, Sabate JM, Bouchoucha M, et al. Association between selfreported vegetarian diet and the irritable bowel syndrome in the French- NutriNet cohort. PLoS One 2017;12:e0183039. https://doi.org/10.1371/journal.pone.0183039
  117. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527-536. https://doi.org/10.1056/NEJMoa1010863
  118. Barshop K, Staller K. Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy. Ther Adv Chronic Dis 2017;8:153-160. https://doi.org/10.1177/2040622317714389
  119. Schumann D, Klose P, Lauche R, Dobos G, Langhorst J, Cramer H. Low fermentable, oligo-, di-, mono-saccharides and polyol diet in the treatment of irritable bowel syndrome: a systematic review and metaanalysis. Nutrition 2018;45:24-31. https://doi.org/10.1016/j.nut.2017.07.004
  120. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170-177. https://doi.org/10.1111/j.1572-0241.2007.01524.x
  121. Fukudo S, Kinoshita Y, Okumura T, et al. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III longterm study. J Gastroenterol 2016;51:874-882. https://doi.org/10.1007/s00535-016-1165-5
  122. Qi Q, Zhang Y, Chen F, Zuo X, Li Y. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and metaanalysis of randomized controlled trials. BMC Gastroenterol 2018;18:5. https://doi.org/10.1186/s12876-017-0734-2
  123. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621-2624.
  124. Choi YJ, Hwang SW, Kim N, Park JH, Oh JC, Lee DH. Association between SLC6A4 serotonin transporter gene linked polymorphic region and ADRA2A 1291C>G and irritable bowel syndrome in Korea. J Neurogastroenterol Motil 2014;20:388-399. https://doi.org/10.5056/jnm14020
  125. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702-1712. https://doi.org/10.1038/ajg.2012.254
  126. Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med 2016;374:242-253. https://doi.org/10.1056/NEJMoa1505180
  127. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:a2313. https://doi.org/10.1136/bmj.a2313
  128. Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt) 2005;14:19-29. https://doi.org/10.1089/jwh.2005.14.19
  129. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol 1998;38:1003-1009. https://doi.org/10.1177/009127009803801103
  130. Kaiser J. Gender in the pharmacy: does it matter? Science 2005;308:1572. https://doi.org/10.1126/science.308.5728.1572
  131. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001;2:349-351. https://doi.org/10.2165/00128071-200102060-00001
  132. Meibohm B, Beierle I. Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002;41:329-342. https://doi.org/10.2165/00003088-200241050-00002
  133. Yamada E, Tsunoda S, Abe T, et al. Factors associated with poor therapeutic response in outpatients with irritable bowel syndrome: a multicenter study in Japan. J Gastroenterol 2017;52:301-307. https://doi.org/10.1007/s00535-016-1215-z
  134. Creed F. The relationship between psychosocial parameters and outcome in irritable bowel syndrome. Am J Med 1999;107(5A):74S-80S.
  135. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-332. https://doi.org/10.1136/gut.2008.167270
  136. Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ. Probiotics and irritable bowel syndrome. World J Gastroenterol 2013;19:5973-5980. https://doi.org/10.3748/wjg.v19.i36.5973
  137. Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 2011;17:252-266. https://doi.org/10.5056/jnm.2011.17.3.252
  138. Zahedi MJ, Behrouz V, Azimi M. Low fermentable oligo-di-monosaccharides and polyols diet versus general dietary advice in patients with diarrhea-predominant irritable bowel syndrome: a randomized controlled trial. J Gastroenterol Hepatol 2018;33:1192-1199. https://doi.org/10.1111/jgh.14051
  139. Lacy BE, Weiser K, Noddin L, et al. Irritable bowel syndrome: patients' attitudes, concerns and level of knowledge. Aliment Pharmacol Ther 2007;25:1329-1341. https://doi.org/10.1111/j.1365-2036.2007.03328.x
  140. Cuomo R, Andreozzi P, Zito FP, Passananti V, De Carlo G, Sarnelli G. Irritable bowel syndrome and food interaction. World J Gastroenterol 2014;20:8837-8845.
  141. Bohn L, Storsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 2015;149:1399-1407.e2. https://doi.org/10.1053/j.gastro.2015.07.054
  142. Jung KW, Seo M, Cho YH. et al. Prevalence of fructose malabsorption in patients with irritable syndrome after excluding small intestinal bacterial overgrowth. J Neurogastroenterol Motil 2018;24:307-316. https://doi.org/10.5056/jnm17044
  143. Kim Y, Choi CH. Role of fructose malabsorption in patients with irritable bowel syndrome. J Neurogastroenterol Motil 2018;24:161-163. https://doi.org/10.5056/jnm18057
  144. Bohn L, Storsrud S, Tornblom H, Bengtsson U, Simren M. Selfreported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol 2013;108:634-641. https://doi.org/10.1038/ajg.2013.105
  145. Varju P, Farkas N, Hegyi P, et al. Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet improves symptoms in adults suffering from irritable bowel syndrome (IBS) compared to standard IBS diet: a meta-analysis of clinical studies. PLoS One 2017;12:e0182942. https://doi.org/10.1371/journal.pone.0182942

Cited by

  1. Gender Difference in Functional Gastrointestinal Disorders vol.72, pp.4, 2018, https://doi.org/10.4166/kjg.2018.72.4.163
  2. IBS common features among Northern Saudi population according to Rome IV criteria vol.6, pp.2, 2018, https://doi.org/10.3934/medsci.2019.2.148
  3. Symptom‐based latent classes of persons with irritable bowel syndrome vol.42, pp.5, 2019, https://doi.org/10.1002/nur.21974
  4. Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis vol.54, pp.11, 2018, https://doi.org/10.1080/00365521.2019.1683226
  5. GABAA receptor currents in the dorsal motor nucleus of the vagus in females: influence of ovarian cycle and 5α-reductase inhibition vol.122, pp.5, 2019, https://doi.org/10.1152/jn.00039.2019
  6. Work-Life Conflict and Its Health Effects on Korean Gastroenterologists According to Age and Sex vol.65, pp.1, 2018, https://doi.org/10.1007/s10620-019-05842-w
  7. Expression of Neurotrophic Factors, Tight Junction Proteins, and Cytokines According to the Irritable Bowel Syndrome Subtype and Sex vol.26, pp.1, 2018, https://doi.org/10.5056/jnm19099
  8. Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis vol.10, pp.None, 2018, https://doi.org/10.3389/fcimb.2020.00468
  9. G Protein-Coupled Estrogen Receptor, GPER1, Offers a Novel Target for the Treatment of Digestive Diseases vol.11, pp.None, 2020, https://doi.org/10.3389/fendo.2020.578536
  10. Low-FODMAP Diet for Irritable Bowel Syndrome: What We Know and What We Have Yet to Learn vol.71, pp.1, 2018, https://doi.org/10.1146/annurev-med-050218-013625
  11. Sex as a biological variable in irritable bowel syndrome vol.32, pp.7, 2018, https://doi.org/10.1111/nmo.13802
  12. Functional Dyspepsia: A Narrative Review With a Focus on Sex-Gender Differences vol.26, pp.3, 2018, https://doi.org/10.5056/jnm20026
  13. Impact of symptom focusing and somatosensory amplification on persistent physical symptoms: A three-year follow-up study vol.135, pp.None, 2020, https://doi.org/10.1016/j.jpsychores.2020.110131
  14. GPER‐mediated, oestrogen‐dependent visceral hypersensitivity in stressed rats is associated with mast cell tryptase and histamine expression vol.34, pp.4, 2018, https://doi.org/10.1111/fcp.12537
  15. Use of genetic testing for hypolactasia trait in the North Denmark Region vol.55, pp.9, 2018, https://doi.org/10.1080/00365521.2020.1800079
  16. Feasibility, acceptability and cost efficiency of using webinars to deliver first‐line patient education for people with Irritable Bowel Syndrome as part of a dietetic‐led gastroenterology vol.33, pp.6, 2020, https://doi.org/10.1111/jhn.12799
  17. Prevalence of Irritable Bowel Syndrome and its Association with Psychological Distress among Female College Students in Korea vol.26, pp.4, 2020, https://doi.org/10.15616/bsl.2020.26.4.351
  18. Aloe barbadensis Mill. extract improves symptoms in IBS patients with diarrhoea: post hoc analysis of two randomized double-blind controlled studies vol.14, pp.None, 2018, https://doi.org/10.1177/17562848211048133
  19. Sex-Gender Differences in the Effectiveness of Treatment of Irritable Bowel Syndrome: A Systematic Review vol.14, pp.None, 2018, https://doi.org/10.2147/ijgm.s291964
  20. Comparing Response of Sheep and Cow Milk on Acute Digestive Comfort and Lactose Malabsorption: A Randomized Controlled Trial in Female Dairy Avoiders vol.8, pp.None, 2018, https://doi.org/10.3389/fnut.2021.603816
  21. Sex-Bias in Irritable Bowel Syndrome: Linking Steroids to the Gut-Brain Axis vol.12, pp.None, 2021, https://doi.org/10.3389/fendo.2021.684096
  22. Aberrant Gut-To-Brain Signaling in Irritable Bowel Syndrome - The Role of Bile Acids vol.12, pp.None, 2018, https://doi.org/10.3389/fendo.2021.745190
  23. Obesity Exacerbates Irritable Bowel Syndrome-Related Sleep and Psychiatric Disorders in Women With Polycystic Ovary Syndrome vol.12, pp.None, 2021, https://doi.org/10.3389/fendo.2021.779456
  24. Sexually dimorphic response of colorectal motility to noxious stimuli in the colorectum in rats vol.599, pp.5, 2021, https://doi.org/10.1113/jp279942
  25. Positive Correlation between nNOS and Stress-Activated Bowel Motility Is Confirmed by In Vivo HiBiT System vol.10, pp.5, 2021, https://doi.org/10.3390/cells10051028
  26. Sex‐based differences in fecal short‐chain fatty acid and gut microbiota in irritable bowel syndrome patients vol.22, pp.5, 2021, https://doi.org/10.1111/1751-2980.12988
  27. Syndrome de l’intestin irritable : Rôle du microbiote intestinal vol.37, pp.6, 2021, https://doi.org/10.1051/medsci/2021095
  28. Sex- and Gender-related Issues of Gut Microbiota in Gastrointestinal Tract Diseases vol.78, pp.1, 2021, https://doi.org/10.4166/kjg.2021.409
  29. Roles of Sex Hormones and Gender in the Gut Microbiota vol.27, pp.3, 2018, https://doi.org/10.5056/jnm20208
  30. Irritable bowel syndrome and migraine: evidence from Mendelian randomization analysis in the UK Biobank vol.15, pp.10, 2021, https://doi.org/10.1080/17474124.2021.1949290
  31. Multispecies probiotics promote perceived human health and wellbeing: insights into the value of retrospective studies on user experiences vol.12, pp.5, 2018, https://doi.org/10.3920/bm2020.0162
  32. Irritable Bowel Syndrome Prevalence among Participants of Woodstock Rock Festival in Poland Based on Rome IV Criteria Questionnaire vol.18, pp.21, 2018, https://doi.org/10.3390/ijerph182111464
  33. Electroencephalographic evidence of unconscious and conscious attentional bias in people with functional gastrointestinal disorders: A pilot study vol.170, pp.None, 2018, https://doi.org/10.1016/j.ijpsycho.2021.09.006
  34. Prevalence and trigger factors of functional gastrointestinal disorders among male civil pilots in China vol.11, pp.1, 2018, https://doi.org/10.1038/s41598-021-81825-0
  35. Physiological mechanisms of unexplained (functional) gastrointestinal disorders vol.599, pp.23, 2018, https://doi.org/10.1113/jp281620
  36. Influence of Irritable Bowel Syndrome on Stress and Depressive Symptoms in Nurses: The Korea Nurses’ Health Study vol.18, pp.23, 2018, https://doi.org/10.3390/ijerph182312324